Abstracts tainty (i.e. expected value of perfect partial information; EVPPI). To perform an EVPPI, two-stage sampling from the original model is required. In practice, it is often not possible to perform an EVPPI because of computer time constraints. OBJECTIVES: The aim of this study is to investigate the usefulness and feasibility of constructing a metamodel to estimate the EVPPI for individual model parameters. METHODS: The metamodel was based on a cost-effectiveness Markov model with 5000 iterations for the treatment of patients with chronic obstructive pulmonary disease. The metamodel constituted a linear regression, using the net monetary benefit of the 5000 simulations as the dependent variable and the input values of the model parameters (e.g. probabilities for exacerbations, hospital admissions, etc.) as independent variables. This regression model was used to calculate the EVPPI for each individual input parameter of the original costeffectiveness model. RESULTS: The EVPI was €3053. The analysis showed that the regression-based metamodel provided a good fit of the original model. The adjusted R2 of the regression model was 98%. The results obtained with the metamodel closely resembled the results of a two-stage sampling EVPPI based on the original model. CONCLUSIONS: In this study, regressionbased metamodel provided reliable estimates of the EVPPI. We conclude that for cost-effectiveness models that meet the linearity criterion, regression based metamodelling promises to be a very efficient and timesaving approach for the calculation of the VOI for individual model parameters.
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MC4 UNCONDITIONAL POWER FOR SECONDARY OBJECTIVES IN A CLINICAL TRIAL
Wang J, Irish WD RTI Health Solutions, Research Triangle Park, NC, USA OBJECTIVES: Sample size estimation in controlled clinical trials is determined to insure that the primary objective can be achieved with certain probability (i.e., power) based on the available information and study assumptions. Power to achieve secondary objectives is usually based on the sample size calculated for the primary objective. If the secondary objectives are evaluated on a sub-sample of the study population, then the sample size becomes a random variable and power is calculated conditioned on the average of sample sizes (i.e., conditional power). This may prove problematic when the sample size for the secondary objectives is different from its mean. We present a method to calculate unconditional power (i.e., power taking into consideration sample size variability) in the situation where secondary objectives are evaluated on a sub-sample of the study population. METHODS: The joint distribution of the test statistics and the sample size for the secondary objectives was considered. Based on the joint distribution, unconditional power of the statistical tests for the secondary objectives was defined. The relationship between unconditional power and traditional power condition on the expectation of the sample size was then explored. RESULTS: By analytical reasoning, we found that conditional power is higher than unconditional power when z-test is used to test the equivalence of two population means with known standard deviation at significant level 0.05. Results can be generalized to other types of statistical tests where the type I error rate is 0.05. CONCLUSIONS: Under the design specifications studied, conditional power was consistently greater than the true power. This may give the researcher an overly optimistic confidence in achieving study results. We will present further results under different design specifications and will highlight situations where conditional power can be used with application to pharmacoeconomic outcomes. (BRTS) . OBJECTIVES: to compare resource utilization and costs of care in BRTS before and after atrial based pacemaker implantation. METHODS: Observational, retrospective, unicenter study included 145 pts (84F; 61M; mean age 68,5) with BRTS, paroxysmal AF and atrial based pacing system (AAI 64,8%; DDD 35,2%) implanted during one year. The data on utilized resources were collected in time window: from 1 year before implantation to 3 years after implantation. The costs were calculated from the public health care payer perspective. RESULTS: During the 3 years after implantation 20 patients died (13.8%) and the cost analysis was performed among survivors. At least one AF episode was reported in 103 pts (82.4%) and 19 (15.2%) had chronic AF at the end of study period. There were 338 AF related hospitalizations before implantation (mean 2.7 per year, per patient) compared to 423 (during 3 years; mean 1.13 per year, per patient; Wilcoxon test p < 0.001). The distribution of costs before implantation was: hospitalizations 82.0%, drugs 10.7%, consultations 4.1%, AF complications (mainly stroke) 3.2% and after implantation: hospitalizations 38.3%, followed by drugs 24.4%, pacing complications costs 21.1%, consultations 6.1%, pacemaker follow-up 4.2% and AF complications 5.9%. The mean annual cost of care of AF decreased after implantation from 3138 PLN (~1569 Euro PPP) to 1923 PLN (~961 Euro PPP) (p < 0.001) and the savings were mainly associated with lower hospitalization rate which was not only economic but also clinical profit. CONCLUSIONS: Atrial based pacing decreases number of hospitalizations and overall costs of therapy in bradycardia-tachycardia syndrome. Hospitalizations due to AF represent the major cost driver in group of patients with brady-tachy syndrome.
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CV1 ATRIAL BASED PACING DECREASES ATRIAL FIBRILLATION RELATED HOSPITALIZATIONS AND COSTS IN BRADY-TACHY SYNDROME
Ruciñski
CV2 COSTS OF CARDIOVASCULAR DISEASE: A CASE-CONTROL STUDY
University of Naples, Naples, Na, Italy; 2 Center of Pharmacoeconomics, Milan, Italy; 3 University of Milan, Milan, Italy OBJECTIVES: The term cerebrovascular disease designates any abnormality of the brain resulting from a pathologic process of the blood vessels. Medical and neurological complications after stroke or transient ischemic attack have a high economic impact. The objectives of the study were to assess the social costs of subjects with cerebrovascular disease, almost one transient ischemic attack or stroke (case) and to compare the costs of these subjects with the costs attributable to subjects without cerebrovascular disease (control). METHODS: Data were collected from a population based naturalistic prospective survey (a representative sample of the Italian general population aged from 40 to 79 years). Subjects with cerebrovascular disease going to general practitioners (GP) were enrolled. We matched each of them by age and sex with controls. We conducted a Cost of Illness (COI)
